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Abstract 
The OVIVA study demonstrated non-inferiority for managing bone and joint infections (BJI) with oral 
antibiotics. We report that 79.7% of OPAT patients being treated for BJI at our centre would be eligible for 
oral antibiotics, saving median 19.5 IV antibiotic days (IQR 8.5-37) and GBP 1,234 (IQR 569-2,594) per 
patient.  
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Introduction 
Bone and joint infections (BJI) are conventionally managed with up to six week courses of antibiotic therapy 
(1–3). Alongside appropriate surgical intervention, intravenous (IV) antibiotics are commonly recommended 
to maximise tissue penetration (1,2). Delivery of IV therapy is increasingly provided by outpatient parenteral 
antimicrobial therapy (OPAT) services enabling earlier discharge from hospital (4). Although OPAT is effective 
and popular (4), it still carries risks of adverse events due to requirements for IV catheters (5) as well as the 
IV antibiotics being administered (6). Therefore, there has been great interest in the potential role of oral 
antibiotics in managing BJI. 
A multi-centre, pragmatic randomised controlled trial (OVIVA study) revealed switching from IV to oral 
antibiotic therapy within 1 week of commencing treatment for BJI was non-inferior, with respect to 
treatment failure, after 1 year of follow up compared with 6 weeks of IV antibiotics to treat a wide range of 
BJI (7). The study extrapolated reductions in IV antibiotic use and cost savings (7). These findings are 
potentially paradigm shifting, but the impact of implementing such a change on real-world practice remains 
unknown. We used the OVIVA study criteria to infer eligibility of patients with BJI in our OPAT service for 
oral antibiotic regimens and assess possible cost savings (5,8). 
 
Methods 
Patient cohort and data extraction 
We utilised data collected prospectively into the OPAT database at University College London Hospitals 
(UCLH) NHS Foundation Trust (5,8). We included all patients with a BJI treated via OPAT between January 
2015 and October 2018. We did not include patients with BJI managed outside of OPAT. Microbiological 
results were extracted from the laboratory information system.  
The study was approved by the Audit and Research Committee at the Hospital for Tropical Diseases, UCLH, 
which stated that, as this was a retrospective review of routine clinical data, formal ethical approval was not 
required.  
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Case review and analysis 
Suitability for an oral regimen was determined by a consultant microbiologist not involved with the OPAT 
service (KK). Clinical diagnosis, microbiological data and allergies were reviewed to ascertain if an effective 
oral antibiotic regimen was available to replace the IV regimen. In the absence of microbiological 
investigations, we constructed empirical oral antibiotic combinations that included clindamycin, 
ciprofloxacin or rifampicin, aiming to cover the most common syndrome-associated causative organisms 
(table S2). We closely mirrored enrolment into the OVIVA study, considering patients not to be suitable for 
an oral regimen if they met any of the stated trial exclusion criteria (7). We classified patients’ surgical 
interventions using the categories presented in the OVIVA trial (7). We considered ineligible a subset of 
patients with a coagulase negative staphylococcal infection (CoNS) where linezolid and/or chloramphenicol 
were the only oral options, based on toxicities related to prolonged use of these drugs.  
Statistical analysis 
We estimated reduction in days of IV treatment and economic savings by following the OVIVA protocol of IV 
therapy being administered for 1 week prior to oral antibiotic switch. We deliver OPAT via community 
nursing services, attendance at hospital clinics or self-administration, depending on patient requirements. 
We considered the median cost of delivering these services, the cost of therapeutic drug monitoring and a 
one-off cost of IV catheter insertion (table S1). We did not include costs of other equipment, such as flushes, 
nor did we assign any costs when patients self-administered. Daily antibiotic costs were derived from our 
hospital pharmacy list pricing for both IV and oral antibiotics (table S1). We did not include the cost of a 
weekly outpatient review, as we assumed this would be indicated irrespective of whether the patient was on 
IV or oral antibiotics. As many patients in our service already receive <6 weeks of IV antibiotics, we also 
estimated hypothetical savings if patients had all in fact received 6 weeks IV therapy. Statistical analysis was 
performed using R v3.4.2. 
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Results 
We identified a total of 133 patients treated for BJI through our OPAT service, comprising approximately a 
quarter of all our OPAT patients (5). Non-vertebral, native osteomyelitis was the most common type of BJI, 
with a range of other native and prosthetic joint infections also being treated (Table 1). The majority of 
patients (74%) underwent a therapeutic or diagnostic surgical procedure (Table 1). Oral antibiotic treatment, 
in line with OVIVA, was considered appropriate for 106 (79.7%) patients. The most common reason patients 
were not eligible was the absence of a suitable oral agent on antibiotic susceptibility testing (n= 14, 10.5%), 
including for 8/18 (44.4%) CoNS infections in our cohort (Table 1).  
Within the ‘oral therapy eligible’ group (n = 106), the two most commonly used IV drugs were ceftriaxone (n 
= 56, 52.9%) and teicoplanin (n = 53, 50%) whilst carbapenems were used in a minority (n = 10, 9.5%) (Table 
S2). Overall a significant proportion of these patients also received rifampicin (n = 43, 40.6%) or ciprofloxacin 
(n = 39, 36.8%). Of 106 ‘oral therapy eligible’ patients, 85 (80.2%) had microbiological data available to guide 
antibiotic choice and 21 (19.8%) did not. A variety of hypothetical oral regimens could be constructed; 
rifampicin and ciprofloxacin (n = 43) was the most common. In the ‘oral therapy eligible’ group, the median 
duration of IV therapy was 26.5 days (IQR 15.5-44) compared with patients who did not meet the criteria for 
oral therapy who received a median of 43 days (IQR 29.5-58, p = 0.02). Both groups received the majority of 
IV therapy through the OPAT service (table 1). 
In our 106 ‘oral therapy eligible’ patients, we estimated 2,589 days of IV treatment saved (median per 
patient 19.5, IQR 8.5-37). Total cost saved was estimated at GBP 185,788 (median GBP 1,234, IQR 569-2,594 
per patient). If all patients had in fact received 6 weeks of IV therapy, rather than median 26.5 days, then the 
estimated median cost saving was GBP 2,950 (IQR 1,725 – 2,950). 
Discussion 
OVIVA provided strong evidence that BJI could be treated with appropriate oral antibiotic regimens, but 
most patients were recruited from two specialist bone and joint infection centres (7). Making use of a well-
defined and prospectively recorded cohort of patients receiving OPAT (5,8), we provide the first real-world 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz991/5585680 by London School of H
ygiene & Tropical M
edicine user on 24 O
ctober 2019
 6 
 
assessment that implementation of comparable criteria rendered the majority (80%) of our BJI cohort 
eligible for oral antibiotic treatment. We had elected not to participate in OVIVA as our practice at the time 
of recruitment was shorter than six weeks of IV therapy, reflected in median IV therapy duration of 29 days 
(IQR 18-45). In addition, inpatients discharged directly on oral antibiotics following short IV antibiotic 
courses were not included in this cohort as they were not referred to the OPAT service. Therefore, IV 
antibiotic and cost savings may be greater in centres routinely using longer courses of IV therapy. Our 
estimation suggests that centres routinely using 6 weeks of IV antibiotics might anticipate savings closer to 
GBP 2-3,000 per patient.  
We estimated that increased use of oral antibiotics would result in significant reductions in IV antibiotic use, 
with ensuing reduced risks associated with IV catheters (5), as well as substantial cost savings. Nevertheless, 
we acknowledge that oral antibiotics still carry risks of adverse events that need monitoring (9). Indeed, our 
cost analysis excluded any reductions in visits to the outpatient department for patients receiving oral 
antibiotics for this reason. We previously demonstrated that both drug and IV catheter associated adverse 
events are uncommon in our cohort (5) and the OVIVA study did not demonstrate differences in the 
incidence of serious adverse events between the two arms (7). Therefore, we did not factor into our cost 
calculations savings associated with reductions in adverse events related to IV antibiotics. However, the 
frequency of adverse events related to IV antibiotics in other cohorts may be greater, and IV antibiotic use 
may be associated with other unrecorded costs, such as complications with IV drug administration in the 
community requiring hospital review. We acknowledge these factors may render our costings an 
underestimate of the true savings of oral antibiotic therapy. 
Our findings were derived from a single OPAT centre, although data were collected prospectively as part of 
routine clinical care and BJI made up a comparable proportion of OPAT cases as elsewhere (10). Despite 
independent review, decisions on oral regimens could not account for patient-specific factors, such as 
unanticipated drug intolerances, and clinician-specific opinions, such as the suitability of beta-lactams for BJI 
(11). We may have overestimated eligibility for oral regimens if a requirement for IV therapy was not 
recorded, such as drug interactions and oral drug intolerance. We considered patients eligible for oral 
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therapy when there was no microbiological diagnosis on sampling (19.8% of our cohort), which was 
comparable to patients in the OVIVA study (20%) (7).   
In conclusion, we present the first assessment of the potential impact of implementing the OVIVA findings in 
a real-world OPAT setting. The majority of patients could have been placed on an oral regimen with 
significant cost savings.  The challenge remains to identify the optimal oral antibiotic regimens and durations 
to effectively deliver excellent clinical outcomes in treatment of BJI (12). 
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Table 1 Characteristics of all OPAT patients being treated for BJI, categorised according to eligibility for 
receiving treatment with oral antibiotic regimens. *The total duration of IV therapy considering both 
inpatient and OPAT IV therapy combined.  ^These estimates were derived from scenario of patients 
receiving a week of IV antibiotics prior to changing to an appropriate oral antibiotic regimen that matched 
the findings of their microbiological investigations. PJI = prosthetic joint infection, OPAT = Outpatient 
parenteral antimicrobial therapy. 
 
 Overall 
(n = 133) 
Eligible for oral 
antibiotics  
(n = 106) 
Not eligible for 
oral antibiotics 
(n = 27) 
Male  92 (68.1%) 74 (69.8%) 18 (66.7%) 
Age in years (IQR) 62 (46 – 71) 62 (42.5-72) 63 (49 – 68) 
Diagnosis Discitis/Vertebral OM 25 23 4 
Diabetic Foot 8 6 2 
Osteomyelitis 52 37 13 
PJI Knee 21 19 2 
PJI Hip 20 16 4 
PJI Other 7 5 2 
Surgical 
interventions 
 
Debridement, antibiotics 
and implant retention 
13 (9.8%) 9 (8.5%) 4 (14.8%) 
No implant or device 
present; debridement of 
chronic osteomyelitis not 
performed 
17 (12.8%) 14 (13.2%) 3 (11.1%) 
No implant or device 
present; debridement of 
chronic osteomyelitis 
performed 
22 (16.5%) 17(16%) 5(18.5%) 
Prosthetic joint implant 
removed 
14 (10.5%) 12 (11.3%) 2 (7.4%) 
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Prosthetic joint implant, 
one-stage revision 
27 (20.3%) 19 (17.9%) 8 (29.6%) 
Removal of orthopaedic 
device for infection 
16 (12%) 15 (14.2%) 1 (3.7%) 
Surgery for discitis, spinal 
osteomyelitis, or epidural 
abscess; debridement 
not performed  
22 (16.5%) 18 (17.0%) 4 (14.8%) 
Surgery for discitis, spinal 
osteomyelitis, or epidural 
abscess; debridement 
performed  
2 (1.5%) 2 (2.2%) 0 (0%) 
Reasons could 
not receive 
oral agent 
Antibiogram of causative 
organism did not offer 
viable oral regimen 
N/A N/A 14 (51.9%) 
 
Staphylococcus aureus 
bacteraemia within the 
preceding 30 days  
N/A N/A 7 (25.9%) 
 Fungal BJI N/A N/A 4 (14.8%) 
 
Allergy to the only oral 
antibiotic regimens 
possible 
N/A N/A 
 
2 (7.4%) 
Duration Total IV Therapy (Median, IQR)* 29 (18-45) 
 
26.5 (15.5-44) 
 
43 (29.5-58.5) 
 
Duration IV OPAT (Median, IQR) 20 (12-34) 17 (11-32) 
 
26 (19-42.5) 
Extrapolated reduced length of IV 
antibiotic therapy per patient (median 
days, IQR) ^ 
N/A 19.5 (8.5-37) 0 
Extrapolated cost saving per patient 
(median GBP, IQR) ^ 
N/A 1,234 (569-2,594) 0 
Extrapolated daily cost saving per patient 
(median GBP, IQR) ^ 
N/A 63 (29 – 133) 0 
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